NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 231 filers reported holding NEVRO CORP in Q4 2020. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $151,242 | +6.8% | 7,869 | +41.3% | 0.00% | – |
| Q2 2023 | $141,564 | -93.4% | 5,569 | -87.9% | 0.00% | -100.0% |
| Q3 2022 | $2,151,000 | +2929.6% | 46,159 | +4586.2% | 0.00% | – |
| Q1 2022 | $71,000 | +222.7% | 985 | +263.5% | 0.00% | – |
| Q4 2021 | $22,000 | -26.7% | 271 | +25.5% | 0.00% | – |
| Q3 2020 | $30,000 | -94.9% | 216 | -96.9% | 0.00% | -100.0% |
| Q3 2019 | $591,000 | -20.5% | 6,871 | -40.1% | 0.01% | -28.6% |
| Q2 2019 | $743,000 | +698.9% | 11,463 | +674.0% | 0.01% | +600.0% |
| Q1 2019 | $93,000 | -35.9% | 1,481 | -18.2% | 0.00% | 0.0% |
| Q2 2018 | $145,000 | -37.8% | 1,810 | -29.5% | 0.00% | -50.0% |
| Q3 2017 | $233,000 | +913.0% | 2,569 | +742.3% | 0.00% | – |
| Q2 2017 | $23,000 | -77.0% | 305 | -71.4% | 0.00% | -100.0% |
| Q1 2017 | $100,000 | +29.9% | 1,068 | +1.2% | 0.00% | 0.0% |
| Q4 2016 | $77,000 | -78.4% | 1,055 | -83.4% | 0.00% | -80.0% |
| Q1 2016 | $357,000 | +243.3% | 6,341 | +184.2% | 0.01% | +400.0% |
| Q3 2015 | $104,000 | – | 2,231 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
| Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
| Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
| Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
| PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
| Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
| Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
| Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
| HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
| FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |